AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00463268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo every 2 weeks
Study NCT02448225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-FDG PET/CT - standard of care
Study NCT02448225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-FSPG PET/CT
Study NCT02448225 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorodeoxyglucose F-18
Description: Undergo 18F-FDG PET/CT - standard of care
Study NCT02448225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 L-glutamate Derivative BAY94-9392
Description: Undergo 18F-FSPG PET/CT
Study NCT02448225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02448225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FDG PET/CT - standard of care
Study NCT02448225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo 18F-FSPG PET/CT
Study NCT02924298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLIMM
Description: Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
Study NCT01430806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dronedarone arm
Description: PO Dronedarone 400 mg BID
Study NCT01430806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dronedarone
Description: Dronedarone PO 400 MG BID
Study NCT02047825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limbs intervention
Description: An 8-week intervention with different exercises will be performed. This intervention will focus on upper limbs. The exercises will include plaster of resistance, elastic bands and other exercises.
Study NCT02047825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment
Description: Occupational therapy and physiotherapy, twice a week, as usual.
Study NCT04749342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Treatment
Description: Physical Therapy sessions for treatment of advanced Lymphedema Cases
Study NCT03214133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epicatechin-rich cocoa dose response
Description: Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.
Study NCT03214133 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Epicatechin-rich cocoa vs placebo on performance
Description: An optimized dose of epicatechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
Study NCT00000125 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topical ocular hypotensive eye drops.
Description: Topical ocular hypotensive eye drops.
Study NCT02859961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 (350 mg)
Description: PRO 140 350 mg (175 mg/mL) SC injection per week
Study NCT02859961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 (525 mg)
Description: PRO 140 525 mg (175 mg/mL) SC injection per week
Study NCT02859961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 (700 mg)
Description: PRO 140 700 mg (175 mg/mL) SC injection per week
Study NCT00889226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
Study NCT00889226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
Study NCT03889431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine capsule
Description: 225 µg of iodine daily as a capsule of potassium iodide
Study NCT03889431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodized Salt
Description: 450 g iodized salt provided for the household weekly. Salt iodine content was 30 to 40 mg iodine /kg salt as KIO3
Study NCT03089554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Intervention
Description: Therapeutic Intervention
Study NCT01603329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing Medication Adherence through Physician Incentives and Messaging
Description: There are two treatments:~1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.~2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.~When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart.
Study NCT02429622 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT simultaneous integrated boost
Description: To achieve a prophylactic dosage and radical dosage once respectively
Study NCT02429622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks
Study NCT02429622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks
Study NCT02429622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Radical esophagectomy 4-6 weeks after neoadjuvant therapy
Study NCT04247009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal based on red meat, fish products or vegan products
Description: Three meals will be served
Study NCT04247009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal based on red meat
Description: Matched Controls will be served only one meal of meat to compare response between (non-RA) matched controls and patients with RA
Study NCT02178553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Study NCT02178553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal Bupivicaine (Exparel)
Study NCT04141254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing and educative components
Description: The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month
Study NCT04141254 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Without debriefing and educative components
Description: Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month
Study NCT03559920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery
Description: The investigators sedate the patients in the ICU for several days after head \& neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.
Study NCT03559920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedate using propofol.
Description: Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
Study NCT00151554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICU-specific information program
Description: The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
Study NCT00764751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 19123 Cream (calcipotriol plus LEO 80122)
Description: Once daily application
Study NCT00764751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovonex® cream
Description: Twice daily application
Study NCT00764751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle
Description: Twice daily application
Study NCT00168480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 100 U, repeated treatments at > 4 month intervals up to Month 32, over a 36-month study period
Study NCT01068925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days
Study NCT00002951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00002951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Study NCT00002951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure
Study NCT00002951 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03875989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior colporraphy
Description: It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.
Study NCT03875989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginal patch plastron
Description: It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.
Study NCT05373303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Erythropoietin Alpha
Description: This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
Study NCT05373303 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Erythropoietin Alpha
Description: This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
Study NCT02945150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
Description: Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those \<75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV).
Study NCT01357577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for PTSD
Description: The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
Study NCT02651051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: 20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal
Study NCT02651051 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: High Fat Breakfast Meal
Description: A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
Study NCT02651051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Breakfast Meal
Description: A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
Study NCT01643954 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: robotic radical prostatectomy
Description: robotic assisted surgery
Study NCT03617965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.
Study NCT02790957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Single injection of 0.24 mg/kg Plerixafor
Study NCT02790957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection of an equal volume of NaCl solution
Study NCT02946632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple combination therapy
Description: Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
Study NCT02946632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stepwise add-on therapy
Description: metformin -> glimepirde -> sitagliptin
Study NCT01636479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR405838
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT02883530 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
Study NCT01749540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luspatercept
Description: subcutaneous injection
Study NCT01807923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet
Study NCT01807923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film-coated tablet
Study NCT01807923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study NCT01449318 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Thermal Sensory Analyzer (Senselab)
Description: Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.~To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.~To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C).
Study NCT01920945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: 155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
Study NCT02403622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Preparation
Description: Frozen processed human fecal material for treating recurrent Clostridium difficile infections.
Study NCT00890929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
Study NCT00890929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
Study NCT04231136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Description: Tegoprazan 50 mg tablet
Study NCT04231136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EAPA115
Description: EAPA115
Study NCT04231136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAPA115
Description: RAPA115
Study NCT03666663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Nasal application using the Sphenocath device- cleared by FDA
Study NCT03666663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Nasal application using the Sphenocath device- cleared by FDA
Study NCT02670681 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: 8 week of aerobic exercise training in different intensities.
Study NCT02515578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced practice transformation support
Study NCT02515578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard practice transformation support
Study NCT02612740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone
Description: cyst removal followed by heterologous bone grafting
Study NCT02612740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: granules of deproteinized bovine bone (Bio-Oss)
Study NCT04465097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26
Study NCT04465097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane: 25 mg QD from week 1 to week 26.
Study NCT04465097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression
Description: If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.
Study NCT03475810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Patients will wear virtual reality glasses and start watching 3 D video after confirmation of adequate motor and sensorial block.
Study NCT03475810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1-2 mg midazolam will be administered before spinal punction performed.